LivaNova (NASDAQ:LIVN) Price Target Cut to $55.00 by Analysts at Robert W. Baird

LivaNova (NASDAQ:LIVN) had its price target reduced by Robert W. Baird from $57.00 to $55.00 in a report issued on Thursday morning, Benzinga reports. They currently have a neutral rating on the stock.

LIVN has been the topic of a number of other reports. Mizuho boosted their target price on shares of LivaNova from $75.00 to $80.00 and gave the stock a buy rating in a report on Thursday, May 2nd. Stifel Nicolaus increased their price target on shares of LivaNova from $70.00 to $72.00 and gave the company a buy rating in a research report on Thursday, July 25th. StockNews.com raised shares of LivaNova from a hold rating to a buy rating in a report on Thursday, April 25th. Finally, Needham & Company LLC upped their target price on shares of LivaNova from $72.00 to $75.00 and gave the company a buy rating in a report on Wednesday, July 31st. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus target price of $65.83.

LivaNova Stock Down 3.6 %

Shares of LivaNova stock traded down $1.67 during trading on Thursday, hitting $45.31. 1,055 shares of the stock traded hands, compared to its average volume of 663,539. The company has a fifty day moving average price of $54.01 and a two-hundred day moving average price of $54.42. LivaNova has a twelve month low of $42.75 and a twelve month high of $64.47. The stock has a market cap of $2.45 billion, a P/E ratio of -78.30 and a beta of 0.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.71 and a current ratio of 3.45.

Insider Buying and Selling at LivaNova

In other news, Director Daniel Jeffrey Moore sold 56,623 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $60.11, for a total value of $3,403,608.53. Following the transaction, the director now directly owns 27,534 shares of the company’s stock, valued at $1,655,068.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On LivaNova

Large investors have recently added to or reduced their stakes in the business. Hexagon Capital Partners LLC boosted its holdings in LivaNova by 117.8% in the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after acquiring an additional 370 shares in the last quarter. Fifth Third Bancorp boosted its holdings in LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after acquiring an additional 332 shares during the period. Lazard Asset Management LLC purchased a new position in shares of LivaNova during the first quarter valued at $84,000. Headlands Technologies LLC lifted its position in shares of LivaNova by 33.3% during the fourth quarter. Headlands Technologies LLC now owns 1,807 shares of the company’s stock valued at $93,000 after buying an additional 451 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in LivaNova in the 1st quarter worth approximately $94,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.